Fingerprint
Dive into the research topics of 'Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically